OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules. One of the company’s proprietary technologies enables cell-free amplification of large DNA molecules, an efficient and easy-to-operate approach that aims to replace the conventional cell-based methodology. It can not only streamline current research processes but also widen the scope of genomics research significantly. In addition to the amplification technology, the company owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology — an emerging field in life sciences in which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide with ever-increasing industrial applications. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.